Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - UBS upgraded M3, Inc (2413:JP) (OTC:MTHRF) from Neutral to Buy and raised its price target to JPY2,840.00 from JPY1,980.00 on Wednesday.
The upgrade reflects UBS’s positive outlook on M3’s margin improvement potential, particularly in the company’s medical platform segment, which focuses on pharmaceutical support business and digital transformation in clinical settings.
UBS increased its price target basis from 22.9X to 33X price-to-earnings ratio, citing upward revisions to earnings forecasts alongside expected margin improvements.
According to UBS’s analysis, M3’s current stock price factors in an operating profit margin of 17-18%, which is below the firm’s forecast of 21% for the fiscal year ending March 2027.
UBS believes the current share price does not fully reflect the anticipated margin improvements that will accompany strong performance in M3’s key business segments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.